CN108653431A - Prevent pharmaceutical composition, preparation method and applications and the preparation of rhinitis - Google Patents
Prevent pharmaceutical composition, preparation method and applications and the preparation of rhinitis Download PDFInfo
- Publication number
- CN108653431A CN108653431A CN201810913288.XA CN201810913288A CN108653431A CN 108653431 A CN108653431 A CN 108653431A CN 201810913288 A CN201810913288 A CN 201810913288A CN 108653431 A CN108653431 A CN 108653431A
- Authority
- CN
- China
- Prior art keywords
- essential oil
- parts
- rhinitis
- preventing
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010039083 rhinitis Diseases 0.000 title claims abstract description 81
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 239000000341 volatile oil Substances 0.000 claims abstract description 250
- 239000003814 drug Substances 0.000 claims abstract description 49
- 239000002994 raw material Substances 0.000 claims abstract description 48
- 241000218378 Magnolia Species 0.000 claims abstract description 32
- 241000272814 Anser sp. Species 0.000 claims abstract description 27
- 241000212948 Cnidium Species 0.000 claims abstract description 26
- 201000010105 allergic rhinitis Diseases 0.000 claims description 37
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 34
- 239000002199 base oil Substances 0.000 claims description 31
- 229940079593 drug Drugs 0.000 claims description 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 10
- 229940119170 jojoba wax Drugs 0.000 claims description 8
- 244000144725 Amygdalus communis Species 0.000 claims description 6
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 6
- 208000036284 Rhinitis seasonal Diseases 0.000 claims description 6
- 239000008168 almond oil Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- -1 patch Substances 0.000 claims description 6
- 239000008169 grapeseed oil Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000007923 nasal drop Substances 0.000 claims description 5
- 229940100662 nasal drops Drugs 0.000 claims description 5
- 239000010497 wheat germ oil Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 3
- 201000008283 Atrophic Rhinitis Diseases 0.000 claims description 3
- 206010039088 Rhinitis atrophic Diseases 0.000 claims description 3
- 244000171263 Ribes grossularia Species 0.000 claims description 3
- 235000002357 Ribes grossularia Nutrition 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000007888 film coating Substances 0.000 claims description 3
- 238000009501 film coating Methods 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 229940040145 liniment Drugs 0.000 claims description 3
- 239000000865 liniment Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000011505 plaster Substances 0.000 claims description 3
- 208000017022 seasonal allergic rhinitis Diseases 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- 229940098465 tincture Drugs 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 59
- 244000025254 Cannabis sativa Species 0.000 abstract description 11
- 231100000957 no side effect Toxicity 0.000 abstract description 8
- 230000002195 synergetic effect Effects 0.000 abstract description 8
- 230000000295 complement effect Effects 0.000 abstract description 4
- 230000000052 comparative effect Effects 0.000 description 33
- 208000024891 symptom Diseases 0.000 description 21
- 239000000243 solution Substances 0.000 description 15
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- 230000008901 benefit Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 9
- 206010028735 Nasal congestion Diseases 0.000 description 8
- 108010058846 Ovalbumin Proteins 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 210000001331 nose Anatomy 0.000 description 8
- 229940092253 ovalbumin Drugs 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 206010039101 Rhinorrhoea Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 229960001340 histamine Drugs 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 206010041232 sneezing Diseases 0.000 description 6
- 206010052437 Nasal discomfort Diseases 0.000 description 5
- 230000003266 anti-allergic effect Effects 0.000 description 5
- 238000001784 detoxification Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000002850 nasal mucosa Anatomy 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000007721 medicinal effect Effects 0.000 description 4
- 208000010753 nasal discharge Diseases 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 230000001314 paroxysmal effect Effects 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 208000036071 Rhinorrhea Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 239000002221 antipyretic Substances 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 238000000518 rheometry Methods 0.000 description 3
- 238000006748 scratching Methods 0.000 description 3
- 230000002393 scratching effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000932 sedative agent Substances 0.000 description 3
- 230000001624 sedative effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 229940126673 western medicines Drugs 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 241000238876 Acari Species 0.000 description 2
- 206010008469 Chest discomfort Diseases 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 2
- 241000475481 Nebula Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 240000002505 Pogostemon cablin Species 0.000 description 2
- 235000011751 Pogostemon cablin Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VPSXHKGJZJCWLV-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(1-ethylpiperidin-4-yl)oxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OC1CCN(CC1)CC VPSXHKGJZJCWLV-UHFFFAOYSA-N 0.000 description 1
- AWFYPPSBLUWMFQ-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=C2 AWFYPPSBLUWMFQ-UHFFFAOYSA-N 0.000 description 1
- 206010001986 Amoebic dysentery Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- NOQGZXFMHARMLW-UHFFFAOYSA-N Daminozide Chemical compound CN(C)NC(=O)CCC(O)=O NOQGZXFMHARMLW-UHFFFAOYSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002206 Daucus carota subsp carota Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 244000025670 Eleusine indica Species 0.000 description 1
- 235000014716 Eleusine indica Nutrition 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 235000014820 Galium aparine Nutrition 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical group O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000244365 Ligusticum sinense Species 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 208000030880 Nose disease Diseases 0.000 description 1
- 206010030111 Oedema mucosal Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000002590 anti-leukotriene effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000005770 birds nest Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000008609 bushi Substances 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000004777 chromones Chemical class 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960002291 clindamycin phosphate Drugs 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229910001679 gibbsite Inorganic materials 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000005765 wild carrot Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于中药技术领域，涉及一种防治鼻炎的药物组合物、制备方法及其应用和制剂。本发明的防治鼻炎的药物组合物，主要由以下重量份的原料制备而成：川芎精油0.1～5份、辛夷精油0.1～5份、蛇床子精油0.05～1份、白藓皮精油0.05～1份、藿香精油0.08～3份和鹅不食草精油0.01～0.3份。本发明利用中医药配伍理论，主要以川芎精油、辛夷精油、蛇床子精油、白藓皮精油、藿香精油、鹅不食草精油为原料，利用组方中精油之间相互配伍发挥协同作用的原理而相辅相成、增强效用，扩大疗效，使得鼻炎治疗效果显著，效果稳定，且无副作用。The invention belongs to the technical field of traditional Chinese medicine, and relates to a pharmaceutical composition for preventing and treating rhinitis, a preparation method, application and preparation thereof. The pharmaceutical composition for preventing and treating rhinitis of the present invention is mainly prepared from the following raw materials in parts by weight: 0.1-5 parts of Chuanxiong essential oil, 0.1-5 parts of magnolia essential oil, 0.05-1 part of Cnidium essential oil, and 0.05-1 part of white moss bark essential oil 0.08 to 3 parts of Huoxiang essential oil and 0.01 to 0.3 parts of goose non-grass essential oil. The present invention utilizes the compatibility theory of traditional Chinese medicine, mainly uses Chuanxiong essential oil, magnolia essential oil, cnidium essential oil, white moss skin essential oil, Huoxiang essential oil and goose herbivorous essential oil as raw materials, and utilizes the mutual compatibility of the essential oils in the formula to play a synergistic effect Principles complement each other, enhance utility, and expand curative effect, so that the rhinitis treatment effect is remarkable, the effect is stable, and there is no side effect.
Description
技术领域technical field
本发明属于中药技术领域，尤其涉及一种防治鼻炎的药物组合物、制备方法及其应用和制剂。The invention belongs to the technical field of traditional Chinese medicine, and in particular relates to a pharmaceutical composition for preventing and treating rhinitis, a preparation method and its application and preparation.
背景技术Background technique
过敏性鼻炎也称为变应性鼻炎，是指特应性个体接触变应原后，主要由IgE介导的介质(主要是组胺)释放，并有多种免疫活性细胞和细胞因子等参与的鼻黏膜非感染性炎性疾病。变应性鼻炎是一种由基因与环境互相作用而诱发的多因素常见疾病，其危险因素可能存在于所有年龄段，且变应性鼻炎是导致成人哮喘的高危因素之一，控制不好的过敏性鼻炎患者中约有三分之一可引发哮喘，所以变应性鼻炎是一个全球性健康问题，给患者工作和生活带来很多痛苦和不便，严重的情况下可导致许多伴发疾病，甚至导致患者劳动力丧失。Allergic rhinitis, also known as allergic rhinitis, refers to the release of mediators (mainly histamine) mediated by IgE after an atopic individual is exposed to an allergen, and a variety of immune active cells and cytokines are involved noninfectious inflammatory disease of the nasal mucosa. Allergic rhinitis is a multifactorial common disease induced by the interaction of genes and the environment, and its risk factors may exist in all age groups, and allergic rhinitis is one of the high risk factors leading to adult asthma, poorly controlled About one-third of patients with allergic rhinitis can cause asthma, so allergic rhinitis is a global health problem, which brings a lot of pain and inconvenience to patients' work and life, and can lead to many accompanying diseases in severe cases. Even lead to patient labor loss.
目前，针对过敏性鼻炎的药物治疗常用抗组胺药、糖皮质激素、抗白三烯药、色酮类药、鼻内减充血剂、鼻内抗胆碱能药物等口服西药来控制病情。采用口服西药能将症状减轻，但却不能完全根治，难以维持，容易反复，停药后无长期持续疗效，然而长期反复地使用这类的药物，容易造成身体的惯性及依赖，可能导致将来的过敏发作时更无法控制，其毒副作用大且成本高，且大部分口服给药引起全身副作用。At present, antihistamines, glucocorticoids, anti-leukotriene drugs, chromones, intranasal decongestants, intranasal anticholinergic drugs and other oral western medicines are commonly used in the drug treatment of allergic rhinitis to control the condition. Oral western medicine can alleviate the symptoms, but it cannot be completely cured, it is difficult to maintain, it is easy to repeat, and there is no long-term sustained effect after stopping the medicine. However, long-term and repeated use of this kind of medicine is likely to cause inertia and dependence of the body, which may lead to future problems. It is even more uncontrollable during the allergic attack, its toxic and side effects are large and the cost is high, and most of the oral administration causes systemic side effects.
中药在治疗过敏性鼻炎上也有较长的历史，具有标本兼治、疗效显著、可避免西药副作用等特点。目前治疗鼻炎的中药成分主要有千柏鼻炎片、霍胆丸、辛苓颗粒等，但有效成分含量低，作用缓慢，疗效不佳，仍不能满足患者的用药需要。另外，目前市面上治疗过敏性鼻炎的中药精油大多数是单方精油加基础油调配制成，作用单一，疗效不显著。Traditional Chinese medicine also has a long history in the treatment of allergic rhinitis. It has the characteristics of treating both symptoms and root causes, significant curative effect, and avoiding the side effects of western medicine. At present, the traditional Chinese medicine components for treating rhinitis mainly include Qianbai Biyan Tablets, Huodan Pills, and Xinling Granules, etc., but the content of active ingredients is low, the action is slow, and the curative effect is not good, which still cannot meet the needs of patients. In addition, most of the traditional Chinese medicine essential oils currently on the market for the treatment of allergic rhinitis are made of a single essential oil plus base oil, which has a single effect and has no significant curative effect.
有鉴于此，特提出本发明。In view of this, the present invention is proposed.
发明内容Contents of the invention
本发明的第一目的在于提供一种防治鼻炎的药物组合物，利用中医药配伍理论，主要以川芎精油、辛夷精油、蛇床子精油、白藓皮精油、藿香精油、鹅不食草精油为原料，利用组方中精油之间相互配伍发挥协同作用的原理而相辅相成、增强效用，扩大疗效，使得抗鼻炎疗效显著，效果稳定，且无副作用。The first object of the present invention is to provide a pharmaceutical composition for preventing and treating rhinitis. Utilizing the compatibility theory of traditional Chinese medicine, mainly using Chuanxiong essential oil, magnolia essential oil, cnidium essential oil, white moss bark essential oil, Huoxiang essential oil and goose non-eating grass essential oil as The raw materials use the principle of mutual compatibility and synergistic effect of the essential oils in the prescription to complement each other, enhance the utility, and expand the curative effect, so that the anti-rhinitis curative effect is remarkable, the effect is stable, and there is no side effect.
本发明的第二目的在于提供一种防治鼻炎的药物组合物的制备方法，制备工序少，操作简便，能够充分发挥各原料的功效，产品稳定性好。The second object of the present invention is to provide a preparation method of a pharmaceutical composition for preventing and treating rhinitis, which has less preparation steps, is easy to operate, can fully exert the efficacy of each raw material, and has good product stability.
本发明的第三目的在于提供一种所述的防治鼻炎的药物组合物在治疗、预防或缓解鼻炎中的应用，使用本发明的防治鼻炎的药物组合物能够更安全有效、长效、便捷的预防、治疗或缓解鼻炎。The third object of the present invention is to provide the application of the pharmaceutical composition for preventing and treating rhinitis in treating, preventing or alleviating rhinitis. Using the pharmaceutical composition for preventing and treating rhinitis of the present invention can be more safe, effective, long-acting and convenient. Prevent, treat or relieve rhinitis.
本发明的第四目的在于提供一种根据所述的药物组合物制备而成的防治鼻炎的药物制剂，有效成分高，治疗鼻炎的疗效显著，安全无副作用，使用方便。The fourth object of the present invention is to provide a pharmaceutical preparation for preventing and treating rhinitis prepared according to the pharmaceutical composition, which has high active ingredients, significant curative effect for treating rhinitis, is safe and has no side effects, and is easy to use.
为了实现本发明的上述目的，特采用以下技术方案：In order to realize the above-mentioned purpose of the present invention, special adopt following technical scheme:
根据本发明的一个方面，本发明提供一种防治鼻炎的药物组合物，主要由以下重量份的原料制备而成：According to one aspect of the present invention, the present invention provides a pharmaceutical composition for preventing and treating rhinitis, which is mainly prepared from the following raw materials in parts by weight:
川芎精油0.1～5份、辛夷精油0.1～5份、蛇床子精油0.05～1份、白藓皮精油0.05～1份、藿香精油0.08～3份和鹅不食草精油0.01～0.3份。0.1-5 parts of Chuanxiong essential oil, 0.1-5 parts of magnolia essential oil, 0.05-1 part of cnidium essential oil, 0.05-1 part of white moss bark essential oil, 0.08-3 parts of Huoxiang essential oil, and 0.01-0.3 parts of Goose Bubivorous essential oil.
作为进一步优选技术方案，主要由以下重量份的原料制备而成：As a further preferred technical solution, it is mainly prepared from the following raw materials in parts by weight:
川芎精油1～3份、辛夷精油1～3份、蛇床子精油0.2～0.5份、白藓皮精油0.1～0.5份、藿香精油0.5～1.5份和鹅不食草精油0.05～0.15份。1-3 parts of Chuanxiong essential oil, 1-3 parts of magnolia essential oil, 0.2-0.5 parts of cnidium essential oil, 0.1-0.5 parts of white moss skin essential oil, 0.5-1.5 parts of Huoxiang essential oil and 0.05-0.15 parts of Goose Bubivorous essential oil.
作为进一步优选技术方案，主要由以下重量份的原料制备而成：As a further preferred technical solution, it is mainly prepared from the following raw materials in parts by weight:
川芎精油1.5～2.5份、辛夷精油1.5～2.5份、蛇床子精油0.25～0.45份、白藓皮精油0.2～0.4份、藿香精油0.85～1份和鹅不食草精油0.05～0.15份。1.5-2.5 parts of Chuanxiong essential oil, 1.5-2.5 parts of magnolia essential oil, 0.25-0.45 parts of cnidium essential oil, 0.2-0.4 parts of white moss bark essential oil, 0.85-1 part of Huoxiang essential oil, and 0.05-0.15 parts of gooseberry essential oil.
作为进一步优选技术方案，还包括基础油92～100重量份，优选的，还包括基础油94～100重量份，进一步优选的，还包括基础油95～100重量份；As a further preferred technical solution, it also includes 92-100 parts by weight of base oil, preferably, also includes 94-100 parts by weight of base oil, and more preferably, also includes 95-100 parts by weight of base oil;
优选地，所述基础油包括甜杏仁油、荷荷巴油、葡萄籽油和小麦胚芽油中的至少一种。Preferably, the base oil includes at least one of sweet almond oil, jojoba oil, grapeseed oil and wheat germ oil.
根据本发明的另一个方面，本发明还提供一种如上所述的防治鼻炎的药物组合物的制备方法，包括以下步骤：According to another aspect of the present invention, the present invention also provides a preparation method of the above-mentioned pharmaceutical composition for preventing and treating rhinitis, comprising the following steps:
将各原料按配方量混合均匀，分装和密封，即得所述防治鼻炎的药物组合物。All raw materials are uniformly mixed according to the formula amount, packaged and sealed to obtain the pharmaceutical composition for preventing and treating rhinitis.
根据本发明的另一个方面，本发明还提供一种所述的防治鼻炎的药物组合物在治疗、预防或缓解鼻炎中的应用。According to another aspect of the present invention, the present invention also provides an application of the pharmaceutical composition for preventing and treating rhinitis in treating, preventing or alleviating rhinitis.
作为进一步优选技术方案，所述鼻炎包括干燥性鼻炎、药物性鼻炎、萎缩性鼻炎、季节性鼻炎和过敏性鼻炎中的至少一种，优选为过敏性鼻炎。As a further preferred technical solution, the rhinitis includes at least one of sicca, drug-induced rhinitis, atrophic rhinitis, seasonal rhinitis and allergic rhinitis, preferably allergic rhinitis.
根据本发明的另一个方面，本发明还提供一种所述的药物组合物制备而成的防治鼻炎的药物制剂。According to another aspect of the present invention, the present invention also provides a pharmaceutical preparation for preventing and treating rhinitis prepared from the pharmaceutical composition.
作为进一步优选技术方案，所述制剂的剂型为外用制剂；As a further preferred technical solution, the dosage form of the preparation is an external preparation;
优选地，所述制剂的剂型为滴鼻剂、凝胶剂、膏剂、贴剂、搽剂、酊剂、洗剂、涂膜剂或贴膏剂。Preferably, the dosage form of the preparation is nasal drops, gel, ointment, patch, liniment, tincture, lotion, film coating or plaster.
作为进一步优选技术方案，所述制剂还包括药学上可接受的辅料；As a further preferred technical solution, the preparation also includes pharmaceutically acceptable excipients;
优选地，所述辅料包括赋形剂、黏合剂、填充剂、润滑剂、抗氧剂、防腐剂和增稠剂中的一种或多种。Preferably, the auxiliary materials include one or more of excipients, binders, fillers, lubricants, antioxidants, preservatives and thickeners.
与现有技术相比，本发明的有益效果在于：Compared with prior art, the beneficial effect of the present invention is:
1、本发明提供的防治鼻炎的药物组合物，利用中医药配伍理论，有针对性的合理配伍，主要以川芎精油、辛夷精油、蛇床子精油、白藓皮精油、藿香精油和鹅不食草精油为原料，各原料组分科学地搭配，各组分之间相互影响，取得协同作用，利用组方中精油之间挥发速度不一的原理而相辅相成、增强效用，扩大疗效，使得抗鼻炎疗效显著，效果稳定，且无副作用。1. The pharmaceutical composition for the prevention and treatment of rhinitis provided by the present invention utilizes the compatibility theory of traditional Chinese medicine to make targeted and reasonable compatibility, mainly using Rhizoma Chuanxiong essential oil, Magnolia magnolia essential oil, Fructus Cnidii essential oil, Moss bark essential oil, Huoxiang essential oil and Goose Bushi Grass essential oil is used as the raw material, and the components of the raw materials are scientifically matched, and the components interact with each other to achieve synergistic effects. Using the principle of different volatilization speeds between the essential oils in the formula, they complement each other, enhance the effectiveness, and expand the curative effect, making anti-rhinitis The curative effect is remarkable, the effect is stable, and there is no side effect.
2、本发明在中医药配伍理论和精油调配技术相结合的基础下，以散风寒、通鼻窍的辛夷精油和解热、镇痛镇静、改善血流变、抗炎的川芎精油为君药，配以祛风、燥湿、杀虫、止痒的蛇床子精油和清热燥湿、祛风解毒的白藓皮精油以及祛暑解表、化湿和胃的藿香精油为臣药，佐以祛风、散寒、胜湿、去翳、通鼻塞的鹅不食草精油为使药，再辅以任选的基础油，制备而成用于防治鼻炎的复方精油组合物，为人们提供了一种天然、安全有效、无毒副作用的药物组合物，对治疗或预防鼻炎有显著效果。2. Based on the combination of Chinese medicine compatibility theory and essential oil blending technology, the present invention uses Magnolia magnolia essential oil for dispelling wind and cold and dredging the nasal orifice, and Rhizoma Rhizoma Chuanxiong essential oil for antipyretic, analgesic and sedative, improving blood rheology, and anti-inflammation. It is combined with cnidium essential oil for dispelling wind, dampness, killing insects and relieving itching, white moss skin essential oil for clearing away heat and dampness, dispelling wind and detoxification, and wagwort essential oil for dispelling summer heat, relieving exterior, removing dampness and regulating stomach. The compound essential oil composition used to prevent and treat rhinitis is prepared by using goose herb essential oil for expelling wind, dispelling cold, eliminating dampness, removing nebula, and unblocking nasal congestion as a medicine, supplemented with optional base oil, and providing people with A natural, safe, effective, non-toxic and side effect pharmaceutical composition has remarkable effects on treating or preventing rhinitis.
3、本发明的组合物经现代工艺加工而成，采用精油为原料，制备方法简单，制备工序少，生产效率高；并且，患者用药方便，可通过鼻腔涂抹给药的方式缓解阵发性喷嚏，消除清水样鼻涕、鼻塞和鼻痒等症状，从根本上解决患者痛苦，疗效显著，副作用低，可降低医疗费用。此外，通过对过敏性鼻炎患者进行治疗证实，本发明的复方精油在治疗过敏性鼻炎方面具有症状迅速缓解，治疗效果好，显著提高患者生活质量的优点，具有良好的应用前景。3. The composition of the present invention is processed by modern technology, using essential oils as raw materials, the preparation method is simple, the preparation process is less, and the production efficiency is high; moreover, it is convenient for patients to take medicine, and can relieve paroxysmal sneezing by nasal smearing and administration , Eliminate symptoms such as clear watery nasal discharge, nasal congestion and nasal itching, and fundamentally solve the pain of patients. It has remarkable curative effect, low side effects, and can reduce medical expenses. In addition, the treatment of allergic rhinitis patients proves that the compound essential oil of the present invention has the advantages of rapid symptom relief, good therapeutic effect, and significantly improved quality of life of patients in the treatment of allergic rhinitis, and has a good application prospect.
4、根据本发明所述的药物组合物制备而成的防治鼻炎的药物制剂，至少具有与上述防治鼻炎的药物组合物相同的优势。4. The pharmaceutical preparation for preventing and treating rhinitis prepared from the pharmaceutical composition of the present invention has at least the same advantages as the above-mentioned pharmaceutical composition for preventing and treating rhinitis.
具体实施方式Detailed ways
下面将结合实施方式和实施例对本发明的实施方案进行详细描述，但是本领域技术人员将会理解，下列实施方式和实施例仅用于说明本发明，而不应视为限制本发明的范围。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。未注明具体条件者，按照常规条件或制造商建议的条件进行。The embodiments of the present invention will be described in detail below in conjunction with the embodiments and examples, but those skilled in the art will understand that the following embodiments and examples are only for illustrating the present invention, and should not be regarded as limiting the scope of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by persons of ordinary skill in the art without making creative efforts belong to the protection scope of the present invention. If the specific conditions are not specified, follow the general conditions or the conditions suggested by the manufacturer.
第一方面，在至少一个实施例中提供一种防治鼻炎的药物组合物，主要由以下重量份的原料制备而成：In the first aspect, in at least one embodiment, a pharmaceutical composition for preventing and treating rhinitis is provided, which is mainly prepared from the following raw materials in parts by weight:
川芎精油0.1～5份、辛夷精油0.1～5份、蛇床子精油0.05～1份、白藓皮精油0.05～1份、藿香精油0.08～3份和鹅不食草精油0.01～0.3份。0.1-5 parts of Chuanxiong essential oil, 0.1-5 parts of magnolia essential oil, 0.05-1 part of cnidium essential oil, 0.05-1 part of white moss bark essential oil, 0.08-3 parts of Huoxiang essential oil, and 0.01-0.3 parts of Goose Bubivorous essential oil.
可以理解的是，本发明所述的鼻炎指典型症状主要是阵发性喷嚏、清水样鼻涕、鼻塞和鼻痒的过敏性鼻炎，即变应性鼻炎。但并不限于此，该药物组合物对其他类型的鼻炎如药物性鼻炎等也具有一定的疗效。It can be understood that the rhinitis described in the present invention refers to allergic rhinitis whose typical symptoms are mainly paroxysmal sneezing, clear watery nasal discharge, nasal congestion and nasal itching, ie allergic rhinitis. But not limited thereto, the pharmaceutical composition also has a certain curative effect on other types of rhinitis such as drug-induced rhinitis.
本发明通过萃取纯天然植物精油，利用中医药配伍理论，首次以川芎精油、辛夷精油、蛇床子精油、白藓皮精油、藿香精油、鹅不食草精油为原料，辅以任选的基础油，调配组合成具有明显缓解并治愈阵发性喷嚏、清水样鼻涕、鼻塞和鼻痒等症状的抗过敏性鼻炎精油配方，气味芳香，制作简单，方便使用，属纯天然物质配方，相比西药而言无毒无副作用，绿色健康、长效，相比于单方精油加基础油调配而成的药物，作用多重，疗效显著，具有广谱性、高效性、快捷性、安全无毒副作用，价格适中等优点。并且针对过敏性鼻炎，本发明的精油药物组合物具有三重疗效：(1)精油具有一定的杀菌除螨的作用，可降低室内的尘螨数量，降低患者接触变应原的几率；(2)精油芳香走窜之性，联合鼻腔给药，直达病灶，作用于鼻粘膜，发挥药效；(3)本复方精油配方具有清热解毒、活血化瘀、宣肺通窍功能，可针对性的治疗中医认为的由肺气虚、卫表不固、风寒乘虚侵入而引起的过敏性鼻炎；相比单方精油，本复方精油在中医药配伍理论基础上，利用组方中精油之间挥发速度不一的原理而相辅相成、增强效用，扩大疗效，抗过敏性鼻炎疗效显著，非常适合受过敏性鼻炎困扰的大众使用。In the present invention, by extracting pure natural plant essential oils and using the compatibility theory of traditional Chinese medicine, for the first time, Chuanxiong essential oils, magnolia essential oils, cnidium essential oils, white moss skin essential oils, Huoxiang essential oils, and goose herbivorous essential oils are used as raw materials, supplemented by optional base oils Oil, blended and combined into an anti-allergic rhinitis essential oil formula that can significantly relieve and cure symptoms such as paroxysmal sneezing, clear watery nasal discharge, nasal congestion and nasal itching. It has a fragrant smell, is simple to make, and is convenient to use. It is a pure natural material formula. Western medicine is non-toxic and has no side effects, green, healthy, and long-acting. Compared with the medicine formulated with unilateral essential oil and base oil, it has multiple functions and significant curative effect. It is broad-spectrum, efficient, fast, safe and non-toxic. The price is moderate. And for allergic rhinitis, the essential oil pharmaceutical composition of the present invention has triple effects: (1) the essential oil has a certain effect of sterilizing and removing mites, which can reduce the number of dust mites in the room and reduce the chance of patients contacting allergens; (2) The aroma of essential oils has a wandering nature, combined with nasal administration, it can reach the focus directly, act on the nasal mucosa, and exert its medicinal effect; (3) This compound essential oil formula has the functions of clearing away heat and detoxification, promoting blood circulation and removing blood stasis, and clearing the lungs. Allergic rhinitis is considered to be caused by lung qi deficiency, weak health surface, and wind and cold taking advantage of the deficiency; compared with single essential oils, this compound essential oil uses the principle of different volatilization speeds between essential oils in the formula on the basis of the theory of compatibility of traditional Chinese medicine However, they complement each other, enhance effectiveness, and expand curative effect. The anti-allergic rhinitis effect is remarkable, and it is very suitable for the public who are troubled by allergic rhinitis.
进一步地讲，本发明选择上述精油为原料的设计思想主要包括：Further, the present invention selects the above-mentioned essential oil as the design idea of raw material mainly includes:
(1)小分子性、高渗透性、亲油抗水透皮吸收：人体表皮的毛孔直径为60-80微米(1000微米＝1毫米)，而精油分子仅为它的1/1000，和人体细胞相比是1/5000000，因此精油会非常迅速地渗透到皮肤及血液中。精油比中草药(提取液、粉等形式)的惨透性要强70倍，因此精油能够非常迅速地渗透到皮肤深层及血液中，3秒可到达表皮层，6秒可到达真皮层，3分钟进入皮下组织，6分钟到达血液进行全身的血液循环，起到净化人体组织、对抗内在细菌的功效。可避免口服药物对肝肾损伤，采用透皮吸收，药力直接渗透病灶，能够迅速缓解症状。(1) Small molecule, high permeability, lipophilic and water-resistant transdermal absorption: the pore diameter of the human epidermis is 60-80 microns (1000 microns = 1 mm), while the essential oil molecule is only 1/1000 of it, and the human body The cell ratio is 1/5000000, so the essential oil will penetrate into the skin and blood very quickly. Essential oils are 70 times more penetrating than Chinese herbal medicines (in the form of extracts, powders, etc.), so essential oils can penetrate deep into the skin and blood very quickly. It can reach the epidermis in 3 seconds, the dermis in 6 seconds, and enter in 3 minutes. The subcutaneous tissue reaches the blood in 6 minutes for the blood circulation of the whole body, which plays the role of purifying human tissue and fighting internal bacteria. It can avoid the liver and kidney damage caused by oral medicine, and adopts transdermal absorption, and the medicine can directly penetrate into the lesion, and can quickly relieve symptoms.
(2)功效强大：精油是草本的精华所在，99.9％的保证了植物的原始功效，由于渗透特别快，药性极高，所以少量就可以将药效发挥到极致，可节约成本，能做到快速见效，药力直达病灶，迅速缓解病症，克服了现有的产品含药量少、难吸收、容易过敏、药味大难接受等缺点。(2) Powerful efficacy: essential oil is the essence of herbs, 99.9% of which guarantees the original efficacy of the plant, because it penetrates very fast and has high medicinal properties, so a small amount can maximize the efficacy of the medicine, which can save costs and achieve It takes immediate effect, and the medicine can directly reach the focus of the disease, quickly relieve the symptoms, and overcome the shortcomings of existing products such as low drug content, difficult absorption, easy allergies, and unacceptable medicinal taste.
(3)100％天然有机植物精华：精油不含人工添加的化学物质，不含防腐剂，是天然的纯植物萃取，天然纯净健康，在萃取过程中只保留原料中最有效的成分，拒绝任何的添加和化学成分，让肌肤享受零污染。随着生活水平的提高，绿色环保理念的不断强化，越来越多追求高品质生活的消费者，因此精油产品越来越受欢迎，精油产品的适应性更好。(3) 100% natural organic plant essence: essential oil does not contain artificially added chemical substances, does not contain preservatives, is a natural pure plant extraction, natural pure and healthy, only retains the most effective ingredients in the raw materials during the extraction process, and rejects any The additives and chemical ingredients allow the skin to enjoy zero pollution. With the improvement of living standards and the continuous strengthening of the concept of green environmental protection, more and more consumers pursue high-quality life, so essential oil products are becoming more and more popular, and the adaptability of essential oil products is better.
(4)更安全，健康无刺激：目前，激素类等西药类药物存在毒副作用强、易产生耐药性和药物残留等问题，临床应用受到很大限制。而植物精油以其绿色、天然、安全、高效等特点成为抗生素的优良替代品，不会给身体带来不必要的副作用，还对于能够提高人体免疫力，增强机体抵抗能力有着积极作用。(4) Safer, healthy and non-irritating: At present, Western medicines such as hormones have problems such as strong toxic and side effects, easy drug resistance and drug residues, and their clinical application is greatly restricted. The plant essential oil has become an excellent substitute for antibiotics due to its green, natural, safe, and high-efficiency characteristics. It will not bring unnecessary side effects to the body, and has a positive effect on improving human immunity and enhancing the body's resistance.
另外，利用鼻腔给药方式的优点与精油的芳香走窜等优点以及本配方中几种精油自身的特性相结合，具有起效快、疗效好、药效稳定，复发率低等特点。In addition, the combination of the advantages of the nasal administration method, the aroma of essential oils and the characteristics of several essential oils in this formula has the characteristics of quick onset, good curative effect, stable drug effect, and low recurrence rate.
下面对本发明中所选用的精油原料的功效及作用进行进一步的说明。The efficacy and effect of the selected essential oil raw materials in the present invention will be further described below.
川芎精油：具有解热、镇痛镇静、改善血流变、保护神经细胞、抗炎、降压等多种药效作用，还具有活血、行气、祛风止痛，改善微循环、扩张血管等功效。本发明中，按重量份数计，川芎精油典型但非限制性的含量为：0.1份、0.2份、0.5份、0.6份、0.8份、1份、1.2份、1.5份、1.6份、1.8份、2份、2.2份、2.5份、2.8份、3份、3.2份、3.5份、3.8份、4份、4.2份、4.5份、4.8份或5份。Ligusticum chuanxiong essential oil: It has various medicinal effects such as antipyretic, analgesic and sedative, improving blood rheology, protecting nerve cells, anti-inflammation, and lowering blood pressure. effect. In the present invention, by weight parts, the typical but non-limiting content of Chuanxiong essential oil is: 0.1 part, 0.2 part, 0.5 part, 0.6 part, 0.8 part, 1 part, 1.2 part, 1.5 part, 1.6 part, 1.8 part , 2 parts, 2.2 parts, 2.5 parts, 2.8 parts, 3 parts, 3.2 parts, 3.5 parts, 3.8 parts, 4 parts, 4.2 parts, 4.5 parts, 4.8 parts or 5 parts.
辛夷精油：辛夷又名望春花，属木兰科植物，具有散风寒的功效，可用于治鼻炎、降血压。因而辛夷精油具有散风寒、通鼻窍的功效。本发明中，按重量份数计，辛夷精油典型但非限制性的含量为：0.1份、0.2份、0.5份、0.6份、0.8份、1份、1.2份、1.5份、1.6份、1.8份、2份、2.2份、2.5份、2.8份、3份、3.2份、3.5份、3.8份、4份、4.2份、4.5份、4.8份或5份。Magnolia essential oil: Magnolia, also known as Wangchunhua, belongs to Magnoliaceae, has the effect of dispelling wind and cold, and can be used to treat rhinitis and lower blood pressure. Therefore, magnolia essential oil has the effect of dispelling wind and cold and dredging the nose. In the present invention, the typical but non-limiting content of magnolia essential oil in parts by weight is: 0.1 part, 0.2 part, 0.5 part, 0.6 part, 0.8 part, 1 part, 1.2 part, 1.5 part, 1.6 part, 1.8 part , 2 parts, 2.2 parts, 2.5 parts, 2.8 parts, 3 parts, 3.2 parts, 3.5 parts, 3.8 parts, 4 parts, 4.2 parts, 4.5 parts, 4.8 parts or 5 parts.
蛇床子精油：蛇床子别名野胡萝卜子，为伞形科植物蛇床的干燥成熟果实，可温肾壮阳，燥湿，祛风，杀虫。蛇床子精油具有祛风、燥湿、杀虫、止痒的作用。本发明中，按重量份数计，蛇床子精油典型但非限制性的含量为：0.05份、0.06份、0.08份、0.1份、0.2份、0.3份、0.4份、0.5份、0.6份、0.7份、0.8份、0.9份或1份。Fructus Cnidii essential oil: Fructus Cnidii, also known as wild carrot, is the dried and mature fruit of Cnidium umbelliferae, which can warm kidney and strengthen yang, dry dampness, dispel wind and kill insects. Fructus Cnidii essential oil has the functions of expelling wind, drying dampness, killing insects and relieving itching. In the present invention, in parts by weight, the typical but non-limiting content of Fructus Cnidii essential oil is: 0.05 part, 0.06 part, 0.08 part, 0.1 part, 0.2 part, 0.3 part, 0.4 part, 0.5 part, 0.6 part, 0.7 part parts, 0.8 parts, 0.9 parts or 1 part.
白藓皮精油：白藓皮为芸香科多年生草本植物白鲜和狭叶白鲜的根皮；具有清热燥湿，祛风解毒的作用；现代研究，该品挥发油在体外有抗癌作用。白藓皮精油具有清热燥湿，祛风，止痒，解毒之功效。本发明中，按重量份数计，白藓皮精油典型但非限制性的含量为：0.05份、0.06份、0.08份、0.1份、0.2份、0.3份、0.4份、0.5份、0.6份、0.7份、0.8份、0.9份或1份。White moss bark essential oil: White moss bark is the root bark of the perennial herbaceous plants of the family Rutaceae, Baixian and Baixian. It has the functions of clearing away heat and dampness, expelling wind and detoxification; modern research shows that the volatile oil of this product has anti-cancer effects in vitro. White moss bark essential oil has the effects of clearing away heat and dampness, expelling wind, relieving itching and detoxification. In the present invention, in parts by weight, the typical but non-limiting content of white moss bark essential oil is: 0.05 part, 0.06 part, 0.08 part, 0.1 part, 0.2 part, 0.3 part, 0.4 part, 0.5 part, 0.6 part, 0.7 parts, 0.8 parts, 0.9 parts or 1 part.
藿香精油：藿香又名合香、苍告、山茴香等，属唇形目，唇形科多年生草本植物；芳香化浊，和中止呕，发表解暑；可用于湿浊中阻，脘痞呕吐，暑湿表证，湿温初起，发热倦怠，胸闷不舒，寒湿闭暑，腹痛吐泻，鼻渊头痛。藿香精油具有祛暑解表、化湿和胃功效，主治鼻渊等症。本发明中，按重量份数计，藿香精油典型但非限制性的含量为：0.08份、0.1份、0.2份、0.4份、0.5份、0.6份、0.8份、1份、1.2份、1.5份、1.6份、1.8份、2份、2.2份、2.5份、2.8份或3份。Patchouli essential oil: Patchouli, also known as Hexiang, Cangsu, and Fennel, is a perennial herb of the Lamiaceae of the order Labiatae; aromatizes turbidity, relieves vomiting, and relieves summer heat; it can be used to block dampness and turbidity, Ruffian vomiting, summer-damp syndrome, early onset of dampness and temperature, fever and fatigue, chest tightness and discomfort, cold-damp blocking of heat, abdominal pain, vomiting and diarrhea, nasal sinusitis headache. Huoxiang essential oil has the functions of dispelling heat, relieving exterior, removing dampness and harmonizing stomach, and it is mainly used to treat rhinorrhea and other diseases. In the present invention, in parts by weight, the typical but non-limiting content of Huoxiang essential oil is: 0.08 parts, 0.1 parts, 0.2 parts, 0.4 parts, 0.5 parts, 0.6 parts, 0.8 parts, 1 part, 1.2 parts, 1.5 parts parts, 1.6 parts, 1.8 parts, 2 parts, 2.2 parts, 2.5 parts, 2.8 parts or 3 parts.
鹅不食草精油：鹅不食草又名猪屎草，为菊科植物石胡荽的带花全草；具有祛风，散寒，胜湿，去翳，通鼻塞的作用；可用于治感冒，寒哮，喉痹，百日咳，痧气腹痛，阿米巴痢，疟疾，疳泻，鼻渊，鼻息肉等。鹅不食草精油具有祛风，散寒，胜湿，去翳，通鼻塞的作用。本发明中，按重量份数计，鹅不食草精油典型但非限制性的含量为：0.01份、0.02份、0.05份、0.06份、0.08份、0.1份、0.12份、0.15份、0.18份、0.2份、0.22份、0.25份、0.28份或0.3份。Goose does not eat grass essential oil: Goose does not eat grass, also known as pig dung grass, is the whole herb with flowers of coriander, a composite plant; it has the functions of dispelling wind, dispelling cold, eliminating dampness, removing shade, and clearing nasal congestion; Cold, asthma, sore throat, whooping cough, abdominal pain caused by Sha gas, amoebic dysentery, malaria, malaria, nasal sinusitis, nasal polyps, etc. Goose Bubivorous essential oil has the functions of expelling wind, dispelling cold, eliminating dampness, removing cloudiness, and clearing nasal congestion. In the present invention, in parts by weight, the typical but non-limiting content of Goose Bubiobi essential oil is: 0.01 part, 0.02 part, 0.05 part, 0.06 part, 0.08 part, 0.1 part, 0.12 part, 0.15 part, 0.18 part , 0.2 parts, 0.22 parts, 0.25 parts, 0.28 parts or 0.3 parts.
上述防治鼻炎的药物组合物，利用中医药配伍理论，有针对性的合理配伍，主要以川芎精油、辛夷精油、蛇床子精油、白藓皮精油、藿香精油和鹅不食草精油为原料，各原料组分科学地搭配，各组分之间相互影响，取得协同作用，为人们提供了一种天然、安全有效、无毒副作用的健康药物组合物，且原料来源广，价格适中，具有广谱性、高效性、快捷性、安全无毒副作用特点，疗效显著、稳定。The above-mentioned pharmaceutical composition for preventing and treating rhinitis utilizes the compatibility theory of traditional Chinese medicine to make targeted and reasonable compatibility. The raw material components are scientifically matched, each component interacts and achieves a synergistic effect, providing people with a healthy pharmaceutical composition that is natural, safe and effective, and has no toxic or side effects. The source of raw materials is wide and the price is moderate. Spectrum, high efficiency, quickness, safety and no side effects, remarkable and stable curative effect.
此外，当上述川芎精油、辛夷精油、蛇床子精油、白藓皮精油、藿香精油和鹅不食草精油采用上述的组分组成和配比时，所述的防治鼻炎的药物组合物中各种成分之间的相互影响，相辅相成，协同作用更佳，更能体现出上述精油原料的价值。In addition, when the above-mentioned chuanxiong essential oil, magnolia essential oil, Cnidium chinensis essential oil, white moss bark essential oil, Huoxiang essential oil and goosebud grass essential oil adopt the above-mentioned component composition and proportioning, each of the pharmaceutical compositions for preventing and treating rhinitis The interaction between the three components complements each other, and the synergistic effect is better, which can better reflect the value of the above-mentioned essential oil raw materials.
在一种优选的实施方式中，主要由以下重量份的原料制备而成：In a preferred embodiment, it is mainly prepared from the following raw materials in parts by weight:
川芎精油1～3份、辛夷精油1～3份、蛇床子精油0.2～0.5份、白藓皮精油0.1～0.5份、藿香精油0.5～1.5份和鹅不食草精油0.05～0.15份。1-3 parts of Chuanxiong essential oil, 1-3 parts of magnolia essential oil, 0.2-0.5 parts of cnidium essential oil, 0.1-0.5 parts of white moss skin essential oil, 0.5-1.5 parts of Huoxiang essential oil and 0.05-0.15 parts of Goose Bubivorous essential oil.
在一种优选的实施方式中，主要由以下重量份的原料制备而成：In a preferred embodiment, it is mainly prepared from the following raw materials in parts by weight:
川芎精油1.5～2.5份、辛夷精油1.5～2.5份、蛇床子精油0.25～0.45份、白藓皮精油0.2～0.4份、藿香精油0.85～1份和鹅不食草精油0.05～0.15份。1.5-2.5 parts of Chuanxiong essential oil, 1.5-2.5 parts of magnolia essential oil, 0.25-0.45 parts of cnidium essential oil, 0.2-0.4 parts of white moss bark essential oil, 0.85-1 part of Huoxiang essential oil, and 0.05-0.15 parts of gooseberry essential oil.
通过合理调整各组分之间的配比，充分发挥各组分之间的协同配合作用，提高了防治鼻炎的药物组合物的治疗疗效，效果稳定，对于治疗、预防或缓解过敏性鼻炎具有更显著的效果。By rationally adjusting the ratio between the components, the synergistic effect between the components is fully brought into play, the curative effect of the pharmaceutical composition for preventing and treating rhinitis is improved, the effect is stable, and it has a better effect on treating, preventing or alleviating allergic rhinitis. significant effect.
在一种优选的实施方式中，防治鼻炎的药物组合物还包括基础油92～100重量份，优选的，还包括基础油94～100重量份，进一步优选的，还包括基础油95～100重量份；按重量份数计，基础油典型但非限制性的含量为：92份、93份、94份、95份、96份、97份、98份、99份或100份。In a preferred embodiment, the pharmaceutical composition for preventing and treating rhinitis also includes 92-100 parts by weight of base oil, preferably, 94-100 parts by weight of base oil, and more preferably, 95-100 parts by weight of base oil Parts; by weight, the typical but non-limiting content of base oil is: 92 parts, 93 parts, 94 parts, 95 parts, 96 parts, 97 parts, 98 parts, 99 parts or 100 parts.
优选地，所述基础油包括但不限于甜杏仁油、荷荷巴油、葡萄籽油和小麦胚芽油中的至少一种。Preferably, the base oil includes, but is not limited to, at least one of sweet almond oil, jojoba oil, grapeseed oil and wheat germ oil.
需要说明的是，本发明对于基础油及基础油的来源没有特殊限制，可以采用上述几种基础油，还可以采用具有相同或类似作用和效果的其他类型的基础油，可以采用其市售商品，也可以采用本领域技术人员熟知的制备方法自行制备。It should be noted that the present invention has no special restrictions on the base oil and the source of the base oil. The above-mentioned base oils can be used, and other types of base oils with the same or similar functions and effects can also be used. , can also be self-prepared by the preparation methods well known to those skilled in the art.
在一种优选的实施方式中，所述的防治鼻炎的药物组合物，主要由以下重量份的原料制备而成：In a preferred embodiment, the pharmaceutical composition for preventing and treating rhinitis is mainly prepared from the following raw materials in parts by weight:
川芎精油1～3份、辛夷精油1～3份、蛇床子精油0.2～0.5份、白藓皮精油0.1～0.5份、藿香精油0.5～1.5份、鹅不食草精油0.05～0.15份和基础油95～100份。1 to 3 parts of Chuanxiong essential oil, 1 to 3 parts of magnolia essential oil, 0.2 to 0.5 parts of cnidium essential oil, 0.1 to 0.5 parts of white moss skin essential oil, 0.5 to 1.5 parts of Huoxiang essential oil, 0.05 to 0.15 parts of goose non-grass essential oil and basic 95-100 parts of oil.
第二方面，在至少一个实施例中提供一种以上所述的防治鼻炎的药物组合物的制备方法，所述方法包括以下步骤：In a second aspect, in at least one embodiment, a method for preparing the above-mentioned pharmaceutical composition for preventing and treating rhinitis is provided, and the method includes the following steps:
将各原料按配方量混合均匀，分装和密封，即得所述防治鼻炎的药物组合物。All raw materials are uniformly mixed according to the formula amount, packaged and sealed to obtain the pharmaceutical composition for preventing and treating rhinitis.
进一步的，该制备方法可以为，先将基础油放入容器内，再按照配方比例(比例由大到小)依次加入各精油原料，然后盖严盖子，用力滚动，使得所有原料充分混合，然后进行分装，加盖密封，即可。Further, the preparation method can be as follows: first put the base oil into the container, then add each essential oil raw material in sequence according to the formula ratio (from large to small), then close the lid tightly, and roll vigorously to make all the raw materials fully mixed, and then Subpackage, cover and seal, and that's it.
上述制备方法流程简单，操作方便，可充分发挥各原料的功效，产品稳定性好，且无需采用复杂的设备系统，容易实现工业化大规模生产。The above-mentioned preparation method has simple process and convenient operation, can give full play to the efficacy of each raw material, has good product stability, and does not need to use complex equipment systems, and can easily realize industrialized large-scale production.
第三方面，在至少一个实施例中提供一种以上所述的防治鼻炎的药物组合物在治疗、预防或缓解鼻炎中的应用。In the third aspect, at least one embodiment provides an application of the above-mentioned pharmaceutical composition for preventing and treating rhinitis in treating, preventing or alleviating rhinitis.
优选地，所述鼻炎包括干燥性鼻炎、药物性鼻炎、萎缩性鼻炎、季节性鼻炎和过敏性鼻炎中的至少一种，优选为过敏性鼻炎。使用本发明的防治鼻炎的药物组合物能够更安全有效、长效、便捷的预防、治疗或缓解鼻炎，尤其是过敏性鼻炎，但并不限于此，对于其他类型的鼻炎同样具有一定的疗效。Preferably, the rhinitis includes at least one of sicca, drug-induced rhinitis, atrophic rhinitis, seasonal rhinitis and allergic rhinitis, preferably allergic rhinitis. The pharmaceutical composition for preventing and treating rhinitis of the present invention can prevent, treat or alleviate rhinitis, especially allergic rhinitis, more safely, effectively, long-term and conveniently, but is not limited thereto, and also has certain curative effect on other types of rhinitis.
第四方面，在至少一个实施例中提供一种根据以上所述的药物组合物制备而成的防治鼻炎的药物制剂。In the fourth aspect, in at least one embodiment, a pharmaceutical preparation for preventing and treating rhinitis prepared according to the above-mentioned pharmaceutical composition is provided.
在一种优选的实施方式中，所述制剂的剂型为外用制剂；In a preferred embodiment, the dosage form of the preparation is an external preparation;
优选地，所述制剂的剂型包括但不限于滴鼻剂、凝胶剂、膏剂、贴剂、搽剂、酊剂、洗剂、涂膜剂或贴膏剂中的任意一种。本发明提供的药物组合物可以制成各种外用制剂，其药效不会发生改变，患者可以根据需要进行选择，适应性更强。优选地，在制备成各类制剂时，还可以添加药学上可接受的辅料；优选地，所述辅料例如可以为赋形剂、黏合剂、填充剂、润滑剂、抗氧剂、防腐剂和增稠剂中的一种或多种。Preferably, the dosage form of the preparation includes, but is not limited to, any one of nasal drops, gel, ointment, patch, liniment, tincture, lotion, film coating or plaster. The pharmaceutical composition provided by the present invention can be made into various external preparations, and its medicinal effect will not change, and patients can choose according to their needs, and the adaptability is stronger. Preferably, when preparing various preparations, pharmaceutically acceptable auxiliary materials can also be added; preferably, the auxiliary materials can be, for example, excipients, adhesives, fillers, lubricants, antioxidants, preservatives and One or more of thickeners.
本发明中，所述药物制剂的使用方法可以为：将制备而成的药物制剂涂敷在鼻翼两侧的迎香穴和/或鼻腔内，稍作按摩吸收，每天早晚各一次，一个疗程(20天)后，症状消失，并痊愈。In the present invention, the method of using the pharmaceutical preparation can be as follows: apply the prepared pharmaceutical preparation on the Yingxiang acupoint on both sides of the nose and/or in the nasal cavity, massage and absorb it for a while, once a day in the morning and evening, one course of treatment ( 20 days), the symptoms disappeared and recovered.
本发明将精油组合物制成外用制剂，利用鼻腔直接给药，与口服给药、手术相比更具有优势，高浓度药物可直接作用于鼻部，直达病灶，快速见效无副作用。In the present invention, the essential oil composition is made into an external preparation, and the nasal cavity is used for direct administration, which has advantages compared with oral administration and surgery. The high-concentration medicine can directly act on the nose and directly reach the lesion, and has quick results and no side effects.
进一步地讲，鼻腔给药的优势为：(1)生物利用度高，与口服给药相比，鼻腔给药可避免药物在胃肠液中降解和肝脏首过效应，生物利用度高。(2)速效，鼻黏膜面积大，黏膜下血管非常丰富，动脉、静脉和毛细血管交织成网状，药液可迅速吸收，从血管进人体循环。(3)使用方便，患者依从性好，与注射给药相比，鼻腔给药使用方便，易于被患者接受，便于自己用药。并且，鼻腔给药方式的优点与精油的芳香走窜等优点以及本发明配方精油自身的特性相结合，起效快、疗效好、药效稳定，复发率低。Further, the advantages of nasal administration are as follows: (1) High bioavailability. Compared with oral administration, nasal administration can avoid drug degradation in gastrointestinal fluid and hepatic first-pass effect, and has high bioavailability. (2) Quick-acting, the area of the nasal mucosa is large, and the submucosal blood vessels are very rich. The arteries, veins and capillaries are intertwined into a network, and the medicinal liquid can be absorbed quickly and enter the human body circulation from the blood vessels. (3) Easy to use and good patient compliance. Compared with injection administration, nasal administration is convenient to use, easy to be accepted by patients, and convenient for self-administration. Moreover, the advantages of the nasal administration method are combined with the advantages of essential oils such as aroma and movement, and the characteristics of the essential oil of the formula of the present invention, so that the onset of action is fast, the curative effect is good, the drug effect is stable, and the recurrence rate is low.
综上，本发明的防治鼻炎的药物组合物、药物制剂与现有技术相比，主要具有以下优势：In summary, compared with the prior art, the pharmaceutical composition and pharmaceutical preparation for preventing and treating rhinitis of the present invention mainly have the following advantages:
(1)本发明在中医药配伍理论和精油调配技术相结合的基础下，以散风寒、通鼻窍的辛夷精油和解热、镇痛镇静、改善血流变、抗炎的川芎精油为君药，配以祛风、燥湿、杀虫、止痒的蛇床子精油和清热燥湿、祛风解毒的白藓皮精油以及祛暑解表、化湿和胃的藿香精油为臣药，佐以祛风、散寒、胜湿、去翳、通鼻塞的鹅不食草精油为使药，再辅以甜杏仁油或荷荷巴油或葡萄籽油或小麦胚芽油为基础油制备而成用于防治鼻炎的复方精油组合物，为人们提供了一种天然、安全有效、无毒副作用的防治鼻炎的药物，对治疗或预防鼻炎有显著效果。(1) On the basis of the combination of Chinese medicine compatibility theory and essential oil blending technology, the present invention uses Magnolia magnolia essential oil for dispelling wind and cold and dredging the nose orifice and Chuanxiong essential oil for antipyretic, analgesic and sedative, improving blood rheology, and anti-inflammation. , together with Cnidium essential oil for expelling wind, dampness, insecticide and antipruritic, white moss bark essential oil for clearing away heat and dampness, expelling wind and detoxification, and Huoxiang essential oil for dispelling heat, relieving exterior, removing dampness and stomach as ministerial medicines. It is prepared with Goose Bubio essential oil for expelling wind, dispelling cold, eliminating dampness, removing nebula and clearing nasal congestion, supplemented with sweet almond oil, jojoba oil, grape seed oil or wheat germ oil as base oil The compound essential oil composition for preventing and treating rhinitis provides people with a natural, safe, effective and non-toxic and side effect medicine for preventing and treating rhinitis, and has remarkable effect on treating or preventing rhinitis.
(2)本发明的药物经现代工艺加工而成，采用精油为原料，制备方法简单，制备工序少，生产效率高；并且，患者用药方便，通过鼻腔涂抹给药的方式缓解阵发性喷嚏，消除清水样鼻涕、鼻塞和鼻痒等症状，从根本上解决患者痛苦。(2) The medicine of the present invention is processed by modern technology, using essential oils as raw materials, the preparation method is simple, the preparation process is few, and the production efficiency is high; and the patient is convenient to use the medicine, and the paroxysmal sneezing is relieved by nasal smearing and administration, Eliminate symptoms such as clear watery nasal discharge, nasal congestion and nasal itching, and fundamentally solve the pain of patients.
(3)通过对过敏性鼻炎患者进行治疗证实，本发明的复方精油在治疗过敏性鼻炎方面具有症状迅速缓解，治疗效果好，显著提高患者生活质量的优点。(3) It is confirmed by treating allergic rhinitis patients that the compound essential oil of the present invention has the advantages of rapid symptom relief, good therapeutic effect and significantly improved patient quality of life in the treatment of allergic rhinitis.
(4)通过本发明的实施，提供给患者这种特定用途的精油组合物，采用精油为原料，制备简单，使患者用药方便，疗效显著，副作用低，降低医疗费用，具有良好的应用前景。(4) Through the implementation of the present invention, the essential oil composition for this specific use is provided to the patient. The essential oil is used as a raw material, which is simple to prepare, convenient for the patient to use, has significant curative effect, low side effects, and reduces medical expenses, so it has a good application prospect.
下面结合具体实施例和对比例，对本发明作进一步说明。Below in conjunction with specific embodiment and comparative example, the present invention will be further described.
实施例1Example 1
一种防治鼻炎的药物组合物，主要由以下重量份的原料制备而成：A pharmaceutical composition for preventing and treating rhinitis, mainly prepared from the following raw materials in parts by weight:
川芎精油1份、辛夷精油2份、蛇床子精油0.45份、白藓皮精油0.5份、藿香精油1份、鹅不食草精油0.05份和荷荷巴油95份(总份数为100份，下同)。1 part of Chuanxiong essential oil, 2 parts of magnolia essential oil, 0.45 parts of cnidium essential oil, 0.5 part of white moss bark essential oil, 1 part of Huoxiang essential oil, 0.05 part of goose herb essential oil and 95 parts of jojoba oil (the total number of parts is 100 parts , the same below).
实施例2Example 2
一种防治鼻炎的药物组合物，主要由以下重量份的原料制备而成：A pharmaceutical composition for preventing and treating rhinitis, mainly prepared from the following raw materials in parts by weight:
川芎精油1.5份、辛夷精油1.5份、蛇床子精油0.5份、白藓皮精油0.5份、藿香精油0.85份、鹅不食草精油0.15份和甜杏仁油95份。1.5 parts of Chuanxiong essential oil, 1.5 parts of magnolia essential oil, 0.5 parts of cnidium essential oil, 0.5 parts of white moss skin essential oil, 0.85 parts of Huoxiang essential oil, 0.15 parts of goose-grass essential oil and 95 parts of sweet almond oil.
实施例3Example 3
一种防治鼻炎的药物组合物，主要由以下重量份的原料制备而成：A pharmaceutical composition for preventing and treating rhinitis, mainly prepared from the following raw materials in parts by weight:
川芎精油3份、辛夷精油1份、蛇床子精油0.2份、白藓皮精油0.2份、藿香精油0.5份、鹅不食草精油0.1份和小麦胚芽油95份。3 parts of Chuanxiong essential oil, 1 part of magnolia essential oil, 0.2 part of cnidium essential oil, 0.2 part of white moss bark essential oil, 0.5 part of Huoxiang essential oil, 0.1 part of goose herb essential oil and 95 parts of wheat germ oil.
实施例4Example 4
一种防治鼻炎的药物组合物，主要由以下重量份的原料制备而成：A pharmaceutical composition for preventing and treating rhinitis, mainly prepared from the following raw materials in parts by weight:
川芎精油1.5份、辛夷精油0.5份、蛇床子精油1.1份、白藓皮精油0.8份、藿香精油0.08份、鹅不食草精油0.02份和葡萄籽油96份。1.5 parts of Chuanxiong essential oil, 0.5 parts of magnolia essential oil, 1.1 parts of cnidium essential oil, 0.8 parts of white moss bark essential oil, 0.08 parts of Huoxiang essential oil, 0.02 parts of goose and herbivorous essential oil and 96 parts of grape seed oil.
实施例5Example 5
一种防治鼻炎的药物组合物，主要由以下重量份的原料制备而成：A pharmaceutical composition for preventing and treating rhinitis, mainly prepared from the following raw materials in parts by weight:
川芎精油2份、辛夷精油2份、蛇床子精油0.8份、白藓皮精油0.3份、藿香精油0.82份、鹅不食草精油0.08份和甜杏仁油94份。2 parts of Chuanxiong essential oil, 2 parts of magnolia essential oil, 0.8 parts of cnidium essential oil, 0.3 parts of white moss bark essential oil, 0.82 parts of Huoxiang essential oil, 0.08 parts of goose herb essential oil and 94 parts of sweet almond oil.
实施例1-5所述的防治鼻炎的药物组合物的制备方法，包括以下步骤：The preparation method of the pharmaceutical composition for preventing and treating rhinitis described in embodiment 1-5, comprises the following steps:
先将基础油放入容器内，再按照配方比例(比例由大到小)依次加入各精油原料，然后盖严盖子，用力滚动，使得所有原料充分混合均匀，然后进行分装，加盖密封，即得。First put the base oil into the container, then add the essential oil raw materials in sequence according to the formula ratio (from large to small), then close the lid tightly, and roll vigorously to make all the raw materials fully mixed evenly, then divide the packaging, cover and seal, Instantly.
对比例1(西药组)Comparative example 1 (western medicine group)
防治鼻炎的西药：克林霉素磷酸酯凝胶。Western medicine for preventing and treating rhinitis: clindamycin phosphate gel.
对比例2－7(单方精油组)Comparative example 2-7 (single essential oil group)
分别以单一精油为原料，与基础油以5：95的重量比例进行混合。A single essential oil is used as a raw material and mixed with base oil at a weight ratio of 5:95.
对比例2中，川芎精油5份和基础油95份；In comparative example 2, 5 parts of Chuanxiong essential oil and 95 parts of base oil;
对比例3中，辛夷精油5份和基础油95份；In comparative example 3, 5 parts of magnolia essential oils and 95 parts of base oils;
对比例4中，蛇床子精油5份和基础油95份；In comparative example 4, 5 parts of Fructus Cnidii essential oils and 95 parts of base oils;
对比例5中，白藓皮精油5份和基础油95份；In comparative example 5, 5 parts of white moss bark essential oils and 95 parts of base oils;
对比例6中，藿香精油5份和基础油95份；In comparative example 6, 5 parts of Huoxiang essential oils and 95 parts of base oils;
对比例7中，鹅不食草精油5份和基础油95份。In comparative example 7, there are 5 parts of goose not eating grass essential oil and 95 parts of base oil.
对比例8Comparative example 8
一种防治鼻炎的药物组合物，主要由以下重量份的原料制备而成：A pharmaceutical composition for preventing and treating rhinitis, mainly prepared from the following raw materials in parts by weight:
川芎精油10份、辛夷精油7份、蛇床子精油1.5份、白藓皮精油1.5份、藿香精油4.5份、鹅不食草精油0.5份和荷荷巴油75份。10 parts of Chuanxiong essential oil, 7 parts of magnolia essential oil, 1.5 parts of cnidium essential oil, 1.5 parts of white moss bark essential oil, 4.5 parts of Huoxiang essential oil, 0.5 parts of goose herb essential oil and 75 parts of jojoba oil.
与实施例1不同的是，本对比例中各精油原料的含量均不在本发明所提供的含量范围内。Different from Example 1, the content of each essential oil raw material in this comparative example is not within the content range provided by the present invention.
对比例9Comparative example 9
一种防治鼻炎的药物组合物，主要由以下重量份的原料制备而成：A pharmaceutical composition for preventing and treating rhinitis, mainly prepared from the following raw materials in parts by weight:
川芎精油1.5份、辛夷精油1.5份、藿香精油1.7份、鹅不食草精油0.3份和荷荷巴油95份。1.5 parts of Chuanxiong essential oil, 1.5 parts of magnolia essential oil, 1.7 parts of Huoxiang essential oil, 0.3 parts of goose non-grass essential oil and 95 parts of jojoba oil.
与实施例1不同的是，本对比例的原料中不含蛇床子精油和白藓皮精油。Different from Example 1, the raw materials of this comparative example do not contain Cnidiac Cnidii essential oil and white moss bark essential oil.
对比例10Comparative example 10
一种防治鼻炎的药物组合物，主要由以下重量份的原料制备而成：A pharmaceutical composition for preventing and treating rhinitis, mainly prepared from the following raw materials in parts by weight:
辛夷精油2.5份、蛇床子精油0.45份、白藓皮精油0.5份、藿香精油1.5份、鹅不食草精油0.05份和荷荷巴油95份。2.5 parts of magnolia essential oil, 0.45 parts of cnidium essential oil, 0.5 parts of white moss bark essential oil, 1.5 parts of Huoxiang essential oil, 0.05 parts of goose herb essential oil and 95 parts of jojoba oil.
与实施例1不同的是，本对比例的原料中不含川芎精油。Different from Example 1, the raw materials of this comparative example do not contain Rhizoma Chuanxiong essential oil.
药理实验Pharmacological experiment
对各实施例和对比例的药物进行药物实验，实验的材料包括：Carry out drug experiment to the medicine of each embodiment and comparative example, the material of experiment comprises:
(1)动物(1) animals
BALB/c小鼠，雌雄各半，22±2g，(排除鼻部疾病)。BALB/c mice, male and female, 22±2g, (excluding nasal diseases).
(2)实验仪器、试剂(2) Experimental instruments and reagents
地塞米松，卵清白蛋白(OVA)，小鼠血清免疫球蛋白E(IgE)含量测定试剂盒，小鼠血清组胺测定试剂盒，DK－S24型电热恒温水浴锅，BioPowerWaveXS型紫外可见酶标仪，AR1140型电子分析天平。Dexamethasone, ovalbumin (OVA), mouse serum immunoglobulin E (IgE) assay kit, mouse serum histamine assay kit, DK-S24 electric heating constant temperature water bath, BioPowerWaveXS UV-visible enzyme label Instrument, AR1140 electronic analytical balance.
(3)实验药物(3) Experimental drugs
分别以实施例1－5和对比例1－10制得的药物作为实验样品；The medicines prepared in Examples 1-5 and Comparative Examples 1-10 were used as experimental samples respectively;
以OVA溶液代替实验样品，作为对照组。The experimental samples were replaced by OVA solution as a control group.
(4)实验方法(4) Experimental method
a)模型建立：实验第1，7，14天每只小鼠分别腹腔注射200μL0.5g/L的OVA溶液以及20g/L的Al(OH)3溶液。从第22天起每只小鼠鼻腔滴注50g/LOVA溶液20μL。连续滴注10d。对照组用生理盐水代替OVA。末次激发30min内观察动物搔鼻、喷嚏、流涕行为以确定造模成功与否。取建模成功的小鼠进行以下b)治疗实验，每组n＝10只。a) Model establishment: 200 μL of 0.5 g/L OVA solution and 20 g/L Al(OH)3 solution were injected intraperitoneally into each mouse on the 1st, 7th, and 14th days of the experiment. From day 22, 20 μL of 50 g/LOVA solution was nasally instilled into each mouse. Continuous infusion 10d. The control group received normal saline instead of OVA. Within 30 minutes of the last stimulation, observe the behaviors of scratching the nose, sneezing, and running nose of the animals to determine whether the modeling is successful or not. The mice successfully modeled were taken for the following b) treatment experiment, n=10 in each group.
b)治疗：b) Treatment:
对照组：连续7d鼻腔滴注50g/LOVA溶液10μL；Control group: nasal instillation of 50g/LOVA solution 10μL for 7 consecutive days;
对比例1西药组(地塞米松)：地塞米松以生理盐水溶解，剂量5mg/kg，OVA刺激前0.5h腹壁注射，10μLOVA滴鼻，同样连续7d；Comparative example 1 western medicine group (dexamethasone): dexamethasone was dissolved in normal saline, the dose was 5 mg/kg, injected into the abdominal wall 0.5 h before OVA stimulation, 10 μ LOVA was instilled nasally, and the same continued for 7 days;
对比例2－7单方精油组：OVA刺激前0.5h20μL单方精油滴鼻，10μLOVA滴鼻，同样连续7d；Comparative example 2-7 unilateral essential oil group: 0.5h before OVA stimulation, 20 μL unilateral essential oil nasal drops, 10 μL LOVA nasal drops, also continued for 7 days;
对比例8－10和实施例1－5：OVA刺激前0.5h20μL各样品精油滴鼻，10μLOVA滴鼻，同样连续7d；Comparative Examples 8-10 and Examples 1-5: before OVA stimulation, 20 μL of each sample’s essential oil was instilled nasally, 10 μL of LOVA was instilled nasally, and the same continued for 7 days;
以上各组动物造模末次激发30min内对各组动物鼻炎症状打分，6h后小鼠眼球取血，血液静置2－3h，4℃下850g离心15min，转移上清液至新管，置于－80℃保存，参考试剂盒说明书用ELISA方法检测鼠血清IgE和组胺的含量。The rhinitis symptoms of animals in each group were scored within 30 minutes after the last stimulation of animal modeling in the above groups. After 6 hours, the blood was collected from the eyeballs of the mice. Store at -80°C, and use the ELISA method to detect the contents of IgE and histamine in mouse serum by referring to the kit instructions.
(5)评价指标及其结果(5) Evaluation indicators and their results
鼻炎症状评分：Rhinitis Symptom Score:
鼻痒：轻搔鼻1－2次为1分，剧烈抓挠鼻面不止3分，介于二者之间为2分；喷嚏：1－3个为1分，4－10个为2分，大于11个为3分；流涕：流至前鼻孔为1分，超出前鼻孔为2分，涕流满面为3分。Nasal itching: 1 point for light scratching of the nose 1-2 times, 3 points for severe scratching of the nasal surface, 2 points for anything in between; sneezing: 1 point for 1-3 scratches, 2 points for 4-10 scratches, greater than 11 points are 3 points; runny nose: 1 point for flow to the front nostril, 2 points for flow beyond the front nostril, 3 points for runny nose.
以上各项指标均采用叠加量化记分法。结果见表一。All the above indicators adopt the overlay quantitative scoring method. The results are shown in Table 1.
小鼠血清IgE和组胺的含量测定，结果见表二。The content of IgE and histamine in mouse serum was determined, and the results are shown in Table 2.
表一小鼠鼻炎症状评分结果Table 1 Score results of rhinitis symptoms in mice
注：与对照组比较，**P<0.01，*P<0.05Note: Compared with the control group, **P<0.01, *P<0.05
由表一可知，本发明制备的抗过敏性鼻炎复方精油药物组合物较对照组有明显缓解过敏性鼻炎症状的作用，且缓解治疗作用高于对比例1西药组。It can be seen from Table 1 that the anti-allergic rhinitis compound essential oil pharmaceutical composition prepared by the present invention has the effect of obviously relieving the symptoms of allergic rhinitis compared with the control group, and the relieving effect is higher than that of the western medicine group of Comparative Example 1.
在对比例2-7单一精油组里，各单一精油均有改善过敏性鼻炎症状的作用，其中川芎精油缓解作用较辛夷精油、蛇床子精油、白藓皮精油、藿香精油、鹅不食草精油强。而由本发明制备的抗过敏性鼻炎复方精油与各单一精油相比，可使得过敏性鼻炎的症状明显缓解，说明本发明配伍药效显著增强，各精油之间有协同增效作用；另外，由对比例8-10和实施例1的对比分析可知，改变组合物中各原料的配比，使得原料的配比不在本发明保护的范围内，或者删除其中的任意一种或多种组分，均会使治疗效果变差。而实施例1-5的组合物评分相近，且实施例3治疗过敏性鼻炎的效果最佳。In the single essential oil group of comparative example 2-7, each single essential oil has the effect of improving the symptoms of allergic rhinitis, and the relief effect of Chuanxiong essential oil is better than magnolia essential oil, cnidium essential oil, white moss essential oil, Huoxiang essential oil, goose not eating grass Essential oils are strong. Compared with each single essential oil, the anti-allergic rhinitis compound essential oil prepared by the present invention can obviously relieve the symptoms of allergic rhinitis, which shows that the compatibility of the present invention is significantly enhanced, and there is a synergistic effect between each essential oil; in addition, by The comparative analysis of Comparative Examples 8-10 and Example 1 shows that changing the ratio of each raw material in the composition makes the ratio of raw materials not within the scope of protection of the present invention, or deleting any one or more components therein, Both will make the treatment effect worse. The scores of the compositions of Examples 1-5 are similar, and Example 3 has the best effect on treating allergic rhinitis.
表二小鼠血清IgE和组胺的含量测定结果Table two mouse serum IgE and histamine content determination results
注：与对照组比较，**P<0.01，*P<0.05Note: Compared with the control group, **P<0.01, *P<0.05
由表二可知，各单一精油和实验组精油组合物以及西药组均能明显抑制血清IgE和组胺含量的增加。其中各单一精油的抑制效果弱于实验组和西药组，进一步说明本发明配伍药效显著增强，各精油之间有协同增效作用；其中实验组的抑制效果稍高于西药组，进一步说明本发明的抗过敏性鼻炎复方精油组合物在疗效上较西药有其独特的优势，除此之外，还有安全、无副作用的优势。It can be seen from Table 2 that each single essential oil, the essential oil composition of the experimental group and the western medicine group can significantly inhibit the increase of serum IgE and histamine content. Wherein the inhibitory effect of each single essential oil is weaker than experimental group and western medicine group, further illustrates that the compatibility drug effect of the present invention significantly strengthens, and there is synergistic effect between each essential oil; Wherein the inhibitory effect of experimental group is slightly higher than western medicine group, further illustrates this invention The anti-allergic rhinitis compound essential oil composition invented has its unique advantages in curative effect compared with western medicines, in addition, it also has the advantages of being safe and having no side effects.
人群试用调查Population Trial Survey
为测试本发明的精油组合物的实际使用效果，选取过敏性鼻炎诊断均符合该疾病的临床诊断标准的患者200例进行人群试用调查。随机分成两组，其中组与组之间没有系统性差异。In order to test the actual use effect of the essential oil composition of the present invention, 200 cases of patients whose diagnosis of allergic rhinitis all met the clinical diagnostic criteria of the disease were selected to carry out a population trial investigation. Randomized into two groups with no systematic differences between groups.
对照组患者采用地塞米松5mg与庆大霉素8万单位的混合液进行雾化吸人治疗，1次/天。实验组患者用本发明的实施例3配制的复方精油涂敷在鼻翼两侧的迎香穴和鼻腔内，稍作按摩吸收，每天早晚各一次。两组患者均以20天为一个疗程，治疗一个疗程。临床治疗结果见表三。The patients in the control group were treated with a mixture of 5 mg dexamethasone and 80,000 units of gentamycin by nebulization, once a day. The patients in the experimental group applied the compound essential oil prepared in Example 3 of the present invention to the Yingxiang acupoint on both sides of the alar of the nose and in the nasal cavity, and massaged for absorption, once a day in the morning and evening. Both groups of patients were treated for one course of treatment, taking 20 days as a course of treatment. The results of clinical treatment are shown in Table 3.
评价标准如下：The evaluation criteria are as follows:
治愈：患者临床症状消失，经鼻镜检查鼻腔内粘膜无水肿及分泌物，患者1年内无复发；Cured: The patient's clinical symptoms disappeared, and there was no edema and secretions in the nasal mucosa by rhinoscopy, and the patient had no recurrence within 1 year;
显效：患者临床症状基本消失，经鼻镜检查鼻腔内粘膜无明显水肿及分泌物，患者1年内有复发；Significantly effective: the patient's clinical symptoms basically disappeared, and there was no obvious edema and secretions in the nasal mucosa by rhinoscopy, and the patient had recurrence within 1 year;
有效：患者临床症状有所改善，经鼻镜检查鼻腔内粘膜水肿及分泌物有所改善；Effective: the patient's clinical symptoms have improved, and nasal mucosal edema and secretions have improved through rhinoscopy;
无效：患者临床症状及体征无变化。Ineffective: The patient's clinical symptoms and signs did not change.
临床总有效率＝(治愈+显效+有效)/总人数*100％。Total clinical effective rate=(cure+markedly effective+effective)/total number*100%.
表三临床疗效对比Table 3 Comparison of Clinical Curative Effects
注：与对照组比较，**P<0.01，*P<0.05Note: Compared with the control group, **P<0.01, *P<0.05
由表三可知，对比两组的临床疗效，用本发明实施例3配制的复方精油治疗临床总有效率为92％，明显高于对照组的88％。As can be seen from Table 3, comparing the clinical curative effects of the two groups, the total clinical effective rate of the compound essential oil prepared in Example 3 of the present invention was 92%, significantly higher than 88% of the control group.
以上可以说明，使用本发明的防治鼻炎的药物组合物能够更安全有效、长效、便捷的预防、治疗或缓解过敏性鼻炎。It can be seen from the above that using the pharmaceutical composition for preventing and treating rhinitis of the present invention can prevent, treat or relieve allergic rhinitis more safely, effectively, long-term and conveniently.
最后应说明的是：以上各实施例仅用以说明本发明的技术方案，而非对其限制；尽管参照前述各实施例对本发明进行了详细的说明，本领域的普通技术人员应当理解：其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分或者全部技术特征进行等同替换；而这些修改或者替换，并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。Finally, it should be noted that: the above embodiments are only used to illustrate the technical solutions of the present invention, rather than limiting them; although the present invention has been described in detail with reference to the foregoing embodiments, those of ordinary skill in the art should understand that: It is still possible to modify the technical solutions described in the foregoing embodiments, or perform equivalent replacements for some or all of the technical features; and these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the technical solutions of the various embodiments of the present invention. scope.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810913288.XA CN108653431B (en) | 2018-08-10 | 2018-08-10 | Pharmaceutical composition for preventing and treating rhinitis, preparation method, application and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810913288.XA CN108653431B (en) | 2018-08-10 | 2018-08-10 | Pharmaceutical composition for preventing and treating rhinitis, preparation method, application and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108653431A true CN108653431A (en) | 2018-10-16 |
| CN108653431B CN108653431B (en) | 2021-06-08 |
Family
ID=63789857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810913288.XA Active CN108653431B (en) | 2018-08-10 | 2018-08-10 | Pharmaceutical composition for preventing and treating rhinitis, preparation method, application and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108653431B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11751722B2 (en) | 2019-02-25 | 2023-09-12 | Sharkninja Operating Llc | Cooking device and components thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1165670A (en) * | 1996-05-22 | 1997-11-26 | 王崇懿 | Chinese medicine for treating rhinitis |
| CN1493351A (en) * | 2003-09-18 | 2004-05-05 | 江苏扬子江药业集团有限公司 | Chinese medicine compound spraying agent for treating acute, chronic nasitis and its preparation method |
| CN1857412A (en) * | 2006-03-09 | 2006-11-08 | 河南省医学科学研究所 | Rhinitis treating spray |
| CN104257752A (en) * | 2014-10-09 | 2015-01-07 | 成都市康飞药业有限公司 | Medicinal composition for treating rhinitis and application thereof |
-
2018
- 2018-08-10 CN CN201810913288.XA patent/CN108653431B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1165670A (en) * | 1996-05-22 | 1997-11-26 | 王崇懿 | Chinese medicine for treating rhinitis |
| CN1493351A (en) * | 2003-09-18 | 2004-05-05 | 江苏扬子江药业集团有限公司 | Chinese medicine compound spraying agent for treating acute, chronic nasitis and its preparation method |
| CN1857412A (en) * | 2006-03-09 | 2006-11-08 | 河南省医学科学研究所 | Rhinitis treating spray |
| CN104257752A (en) * | 2014-10-09 | 2015-01-07 | 成都市康飞药业有限公司 | Medicinal composition for treating rhinitis and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 徐杰军: "《病毒病常用中药药理与临床》", 30 April 2005, 四川科学技术出版社 * |
| 李晓波等: "鼻通宁滴剂中挥发油含量的GC法测定", 《黑龙江医药》 * |
| 王辉武: "《老医真言》", 31 July 2014, 中国中医药出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11751722B2 (en) | 2019-02-25 | 2023-09-12 | Sharkninja Operating Llc | Cooking device and components thereof |
| US11766152B2 (en) | 2019-02-25 | 2023-09-26 | Sharkninja Operating Llc | Cooking device and components thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108653431B (en) | 2021-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011026267A1 (en) | Antiphlogistic, antioncotic and analgesic chinese herbal composition,preparative method and usage thereof | |
| CN103239662B (en) | Parasite expelling Chinese herbal preparation for animals | |
| CN104857290A (en) | Traditional Chinese medicine disinfection ointment for treating scalds and burns and preparation method thereof | |
| CN104840635A (en) | Chinese herbal medicine eye drops for relieving eyestrain and preparation method thereof | |
| CN104096141A (en) | Traditional Chinese medical composition for treating allergic conjunctivitis | |
| CN110721303A (en) | Traditional Chinese medicine composition for treating allergic rhinitis and application thereof | |
| CN108403932B (en) | Traditional Chinese medicine compound external preparation for treating hormone-dependent dermatitis and preparation method and application thereof | |
| CN108686009A (en) | Prevent and/or treat essential oil composition, preparation method, application and the preparation of rhinitis | |
| CN104825941B (en) | A kind of herbal composite and preparation method thereof for treating tinea pedis | |
| CN108853277A (en) | A kind of Traditional Chinese medicine disinfectant for acupuncture | |
| CN106421392A (en) | Traditional Chinese medicinal gel for treating bedsore and preparation method of traditional Chinese medicinal gel | |
| CN115381912B (en) | External traditional Chinese medicine compound preparation for reducing cancer pain and preparation method thereof | |
| CN108653431A (en) | Prevent pharmaceutical composition, preparation method and applications and the preparation of rhinitis | |
| CN105232413A (en) | Mugwort extraction solution toothpaste | |
| CN107648444A (en) | A kind of slow release cutaneous penetration for vulva seborrhea pastes | |
| CN105617322A (en) | Traditional Chinese medicine composition for treating psoriasis and preparation method thereof | |
| CN106540051B (en) | Treat Chinese medicine composition, pulvis and the paste and preparation method thereof of rhinitis | |
| CN105456708B (en) | Medicine for treating cheilitis and preparation method thereof | |
| CN106188083B (en) | Method for extracting 1, 8-cineole volatile oil from folium artemisiae argyi | |
| CN104825566B (en) | A kind of bee needle attenuation synergistic oral liquid and preparation method thereof | |
| CN104873723B (en) | Cinnamon oil-containing medicine for treating burns and scalds | |
| CN109908109A (en) | A kind of anti-inflammatory analgesic emplastrum and preparation method thereof | |
| CN106362084B (en) | Dong's medicine for preventing gynecological diseases | |
| CN105748685A (en) | Beriberi bacteriostat and preparation method thereof | |
| CN105287977A (en) | Sweet basil herb and aloe composition and preparation as well as preparation method and application of sweet basil herb and aloe composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |